This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Access the science, technology and contacts that you need to accelerate your biologics and novel products towards commercial success.

BioProcessing Bites: the mini webinar series on bioprocess innovation

Share this article

BioProcessing Bites is a live mini webinar series showcasing cutting-edge technologies which are transforming biopharmaceutical development and production. In anticipation of the first of the series, a double bill arriving May 5, we’re excited to reveal details of the sessions below. Each webinar is free to attend by clicking here.

Spent Media Analysis At-Line, Anytime with the Rebel

There is a need for advanced process analytic technologies that can monitor essential bioreactor nutrients and cellular metabolites alongside bioreactors in process development labs. We will explore the applications of a new benchtop analyzer that enables wide (>30 analytes) and rapid analysis of cell media with just ten microliters of sample.

Novel Approach to Real-Time Biophysical Characterization

We will learn about a PAT compatible tool that can characterize higher order structures, quantitate high titer proteins biologics and perform carbohydrate analysis, and how mid-IR laser spectroscopy is enabling real-time biophysical characterization.


  • Glenn A. Harris, Director of Integrated Life Sciences, 908 Devices
  • Craig Magee, PhD, Director, Business Development - Life Sciences, DRS Daylight Solutions
  • Santosh Hodawadekar, PhD, Director, Biopharma Applications, DRS Daylight Solutions

Register for the BioProcessing Bites Mini Webinar Series

Share this article

Upcoming event

BioProcess International Europe

09 - 12 Apr 2024, Messe Wien Congress Centre, Vienna

Europe’s Leading BioProcessing Event for Accelerating Next Generation mAbs, Novel Modalities and ATMPs to Commercial Success

Go to site